$GANX

$1.17 +$0.02 (1.74%) Close

$GANX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 43.6M shares outstanding

Who owns GANX?

By type of holder

Institutions 81.8% Everyone else 18.2%

No insider has reported a holding in the last two years, so insiders are counted in "Everyone else".

Concentration Top 10 holders own 50.8%

Morgan Stanley 18.7% · Saba Capital Management, L.P. 10.7%

Institutional ownership

81.8%

+0.2 pts vs last qtr

Institutional holders

223

+13 vs last qtr

Net shares bought

+97.3K

by institutions in Q2 2026

New / sold out

29 / 16

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Gsa Capital Partners LLP +319.7K
Marshall Wace, LLP +153.8K

Biggest sellers in Q2 2026

Susquehanna International Group, LLP SOLD OUT −439.3K
Saba Capital Management, L.P. −427.0K

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for Gain Therapeutics Inc in the last 12 months.

Is your stake being diluted?

Diluted share count, FY2021–FY2025

+224.3%

+34.20% a year

Each share's claim on the business

−69.2%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $9.82M

over 5 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years47% 3–5 years10% 1–3 years34% Under 1 year9%

Quarterly turnover

5.2%

of institutional shares changed hands

Top 10 managers, median time held

4.3 years

Super Investors

Investment managers reporting GANX on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
MS Morgan Stanley	8.2M	18.70%	−73.6K (−0.9%)	≤2021	0.0%
Shares held by quarter Peak holding8.5M (Q3'25) Change over 8 quarters+423.8K Share of the company18.700% Morgan Stanley's full portfolio →
SC Saba Capital Management, L.P.	4.7M	10.72%	−427.0K (−8.4%)	2023	3.5%
Shares held by quarter Peak holding6.8M (Q2'25) Change over 8 quarters−615.9K Share of the company10.720% Saba Capital Management, L.P.'s full portfolio →

Morgan Stanley

8.2M

% of company

18.70%

Change vs last qtr

−73.6K (−0.9%)

Held since

≤2021

Saba Capital Management, L.P.

4.7M

% of company

10.72%

Change vs last qtr

−427.0K (−8.4%)

Held since

2023

28 more super investors behind a free account

See every manager holding Gain Therapeutics Inc, how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting GANX on Form N-PORT; together they hold 4.6% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
SC Saba Closed-End Funds ETF Exchange Listed Funds Trust	$14.2M	485.5K	1.11%	3.36%	May 31, 2026
CS Cohen & Steers Closed-End Opportunity Fund, Inc. Cohen & Steers Closed-End Opportunity Fund, Inc.	$8.08M	274.9K	0.63%	2.12%	June 30, 2026

Saba Closed-End Funds ETF

Exchange Listed Funds Trust

Position value

$14.2M

% of company

1.11%

% of the fund

3.36%

As of

May 31, 2026

Cohen & Steers Closed-End Opportunity Fund, Inc.

Position value

$8.08M

% of company

0.63%

% of the fund

2.12%

As of

June 30, 2026

17 more funds behind a free account

See every fund holding Gain Therapeutics Inc and how much of the fund the position is.

Comments